Adjuvant Pembro Success in Early Melanoma Raises Questions Adjuvant Pembro Success in Early Melanoma Raises Questions
Adjuvant pembrolizumab significantly improved recurrence-free survival in stage 2B/C melanoma in KEYNOTE 716, but which patients benefit most and what does this mean for treatment down the line?Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news